SCHEDULE: Janus Henderson Boosts Mereo BioPharma Stake

Janus Henderson Group PLC and its affiliate report significant beneficial ownership in Mereo BioPharma Group PLC, holding 11.1% and 9.6% respectively of American Depositary Shares.

Summary

• Janus Henderson Group PLC reported beneficial ownership of 17,688,592 American Depositary Shares (ADS) of Mereo BioPharma Group PLC.
• This ownership by Janus Henderson Group PLC represents 11.1% of the class of securities.
• Janus Henderson Group PLC holds shared voting power and shared dispositive power over these 17,688,592 shares.
• Janus Henderson Biotech Innovation Master Fund Ltd reported beneficial ownership of 15,203,597 ADS of Mereo BioPharma Group PLC.
• This ownership by Janus Henderson Biotech Innovation Master Fund Ltd represents 9.6% of the class of securities.
• Janus Henderson Biotech Innovation Master Fund Ltd holds shared voting power and shared dispositive power over its 15,203,597 shares.
• The reported ownership percentages are calculated as of June 30, 2025.
• The reporting persons certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing is a routine beneficial ownership report (Schedule 13G Amendment), which is primarily factual and does not contain performance or operational updates. The presence of a significant institutional investor like Janus Henderson can be viewed as a neutral to slightly positive signal for the company's stock, indicating institutional interest, but the filing itself is not inherently positive or negative about the company's prospects.

Positives

• Significant institutional ownership by Janus Henderson, a reputable investment firm, which can signal confidence in Mereo BioPharma Group PLC.
• The passive nature of the ownership, indicated by the Schedule 13G filing, suggests the investor is not seeking to influence or change control of the company.

Future Outlook

This filing is a beneficial ownership report and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing reflects a common practice where large asset managers like Janus Henderson hold significant, passive stakes in publicly traded companies, particularly in specialized sectors like biotechnology, through various funds and entities. Such filings provide transparency on institutional investor positions.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional holders, which can influence market perception and liquidity.
• Management: Awareness of a large, passive institutional holder in the company's stock.

Key Dates

Keywords

Mereo BioPharma, Janus Henderson, Biotech, Investment, Ownership, SEC Filing, Schedule 13G, ADS, Institutional Investor